vTv Therapeutics (VTVT): Notes From KOL Call - Piper Jaffray

October 14, 2016 7:15 AM EDT
Get Alerts VTVT Hot Sheet
Price: $5.41 -0.55%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade VTVT Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of vTv Therapeutics (NASDAQ: VTVT) after hosting a KOL call with a doctor considered to be broadly experienced in diabetes research and clinical-stage Type 2 diabetes drug development programs.

This thought leader provided value-added perspectives on the 6-month Phase IIb results from vTv’s ‘399 which demonstrated clinically meaningful and durable efficacy as well as clean safety. Given ‘399’s differentiated liver-selective mechanism and as yet unpublished clinical observations, the KOL suggested that vTv may have overcome central challenges with past GKa efforts. The KOL’s confidence underscores the view that full Phase IIb results could differentiate the candidate within the GK-activator class and may be predictive of success in Phase III - both of which should make ‘399 an attractive partnering candidate. In advance of published ‘399 results in late’16/early’17, and Phase II TTP-273 data by YE16, the analyst sees upside to the Alzheimer’s-based valuation from these novel diabetes candidates.

No change to the price target of $24.00

For an analyst ratings summary and ratings history on vTv Therapeutics click here. For more ratings news on vTv Therapeutics click here.

Shares of vTv Therapeutics closed at $6.64 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Piper Jaffray, Charles Duncan

Add Your Comment